[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356571-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356571-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","egfr-andar-expression-and-coexpression-in-indian-triple-negative-breast-cancer-with-patient-outcome-association","EGFR andAR expression and coexpression in Indian triple-negative breast cancer with patient outcome association","","Triple-negative breast cancer (TNBC) is a heterogeneous disease with limited established molecular targets. To map molecular diversity in Indian TNBC, 93 tumor samples were analyzed for EGFR, CK5/6, and androgen receptor (AR) expression, and results were linked to clinicopathological parameters and patient outcomes. EGFR appeared in 65% and AR in 38% of tumors; EGFR-positive cases were higher grade and showed vimentin positivity with a trend to shorter DFS. AR-positive tumors showed lower vimentin but a poorer survival trend. EGFR–AR coexpression occurred in ~25% at tissue level and ~15% at the doublepositive cellular level by multiplex immunofluorescence, with doublepositive cells associated with poorer DFS. Single-cell RNA sequencing in independent cohorts supported EGFR+AR+ tumor cells at lower frequencies (0.8–5%). These findings suggest EGFR–AR coexpression defines an exploratory group with therapeutic implications and motivate population-specific molecular profiling and potential dual-pathway targeting for clinical research in India.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/egfr-andar-expression-and-coexpression-in-indian-triple-negative-breast-cancer-with-patient-outcome-association/356571/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/egfr-andar-expression-and-coexpression-in-indian-triple-negative-breast-cancer-with-patient-outcome-association/356571.png","ImageObject",300,407,{"name":42,"@type":43},"Connor ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What molecular targets were analyzed in this Indian TNBC cohort?","Question",{"text":63,"@type":64},"The study analyzed EGFR, CK5/6, and androgen receptor (AR) expression in 93 tumor samples, then evaluated associations with clinical features and patient outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How common were EGFR and AR expression in the tumors?",{"text":68,"@type":64},"EGFR expression was detected in 65% of tumors, while AR expression was found in 38%.",{"name":70,"@type":61,"acceptedAnswer":71},"What was observed regarding co-expression of EGFR and AR and patient outcomes?",{"text":72,"@type":64},"Approximately 25% of tumors showed EGFR and AR coexpression at the tissue level, and ~15% contained doublepositive tumor cells by multiplex immunofluorescence; patients with such doublepositive cells showed a trend toward poorer disease-free survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356571,1790340476,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEGFR andAR expression and coexpression in Indian triple-negative breast cancer with patient outcome association  \nPoojaVaid1,2, Anirudha Puntambekar3, Pranali Kanse1,4, Shweta Kadu1,4, PiyushAgrawal5, Aditi Khatpe1,6, Rituja Banale1,4, Ruhi Reddy1,4, DevakiA. Kelkar1,4, Sridhar Hannenhalli7, L. S. Shashidhara1,2,8,9, Chaitanyanand Koppiker1,4 & Madhura Kulkarni1,4,10􀀍  \nTriple negative breast cancer (TNBC) is a highly heterogeneous disease lacking established molecular targets. Its incidence is notably higher in Indian women compared to Western populations. To characterize molecular diversity within Indian TNBCs, we analyzed 93 tumor samples for the expression of EGFR, CK5/6, and androgen receptor (AR) and examined their association with clinicopathological parameters and patient outcomes. EGFR expression was detected in 65% of tumors andAR in 38%. EGFR-positive tumors were of higher grade and had a significant association with vimentin positivity and were associated with a trend toward shorter disease-free survival (DFS). ARpositive tumors exhibited lower vimentin expression, suggesting a less mesenchymal phenotype, but paradoxically showed a trend toward poorer survival. Approximately 25% of the tumors displayed coexpression of EGFR andAR at the tissue level, and 15% contained EGFR-positive, AR-positive, doublepositive tumor cells, as detected by multiplex immunofluorescence. Patients harboring such doublepositive cells showed a trend towards poorer DFS. Single-cell RNA-sequencing data from independent TNBC cohorts confirmed the presence of EGFR + AR+ tumor cells at lower frequencies (0.8-5%). These findings suggest that EGFR-AR co-expression inTNBC tumors is defined as an exploratory group with potential therapeutic implications to combat the increased risk of recurrence. Our results underscore the importance of population-specific molecular profiling inTNBC and suggest that dual targeting of the EGFR andAR pathways may be a promising direction for clinical research in Indian breast cancer patients.  \nKeywords Basal TNBC, EGFR, AR, co-expression of EGFR and AR, Molecular profile  \nAbbreviations  \nTNBC Triple-negative breast cancer EGFR Epidermal Growth Factor Receptor AR Androgen receptor  \nIHC Immunohistochemistry  \nDFS Disease-free survival  \nOS Overall survival  \npCR pathological Complete response  \n1Centre for Translational Cancer Research: a joint initiative of Indian Institute of Science Education and Research (IISER) Pune and Prashanti Cancer Care Mission (PCCM) Pune, Pune, India. 2Department of Biological Sciences, Ashoka University, Sonipat, India. 3Sahyadri Hospitals PVT Ltd, Pune, India. 4Prashanti Cancer Care Mission, Pune, India. 5Division of Medical Research, SRM Medical College Hospital & Research Centre, SRMIST, Kattankulathur, Chennai, India. 6School of Medicine, IUPUI, Indianapolis, IN, USA. 7Cancer Data Science Laboratory, Center for Cancer Research, NCI, NIH, Bethesda, USA. 8Department of Biology, Indian Institute of Science Education and Research, Pune, India. 9National Centre for Biological Sciences, Bangalore, India. 10Centre for Translational Cancer Research, Indian Institute of Science Education and Research (IISER) Pune and Prashanti Cancer Care Mission, Third Floor, Main Building Dr Homi Bhabha Road, Pashan, Pune 411008, Maharashtra, India. 􀀍 email: [madhura.kulkarni@prashanticancercare.org](madhura.kulkarni@prashanticancercare.org)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nTriple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer, i.e., it presents more often with high-grade disease, node involvement, and early recurrence1–3. Globally, TNBC accounts for 10–17% of breast cancers2, but in India, the incidence is significantly higher at 22–27%4–6. Despite the high burden, molecular heterogeneity within Indian TNBC cohorts has not been extensively character","cbCaie95aTw4uyNl","https://ap.wps.com/l/cbCaie95aTw4uyNl","pdf",3287485,16,"English","# Introduction\n## Background on TNBC incidence and treatment in India\n## EGFR, AR, and TNBC molecular subtypes\n## Study aims\n# Materials and methods\n## Patient cohort and study design","[{\"question\":\"What molecular targets were analyzed in this Indian TNBC cohort?\",\"answer\":\"The study analyzed EGFR, CK5/6, and androgen receptor (AR) expression in 93 tumor samples, then evaluated associations with clinical features and patient outcomes.\"},{\"question\":\"How common were EGFR and AR expression in the tumors?\",\"answer\":\"EGFR expression was detected in 65% of tumors, while AR expression was found in 38%.\"},{\"question\":\"What was observed regarding co-expression of EGFR and AR and patient outcomes?\",\"answer\":\"Approximately 25% of tumors showed EGFR and AR coexpression at the tissue level, and ~15% contained doublepositive tumor cells by multiplex immunofluorescence; patients with such doublepositive cells showed a trend toward poorer disease-free survival.\"}]","EGFR andAR expression and coexpression in Indian triple-negative breast cancer with patient outcome association | PDF",1790126014,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0929917df097b45ac2e3aa2998415230.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d00edbdf3d5bf9115ef63b82a74130e9.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a05a7499b58783953a81c554e8c38908.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/379b1a519f1ddf591f0693c72e33c904.webp",980,1287]